COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI) (ADVANCE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01216995
Recruitment Status : Completed
First Posted : October 8, 2010
Last Update Posted : November 21, 2014
Information provided by (Responsible Party):
Cytori Therapeutics

Brief Summary:
Double blind, prospective, randomized, placebo-controlled Safety and Efficacy trial of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction (STEMI).

Condition or disease Intervention/treatment Phase
Acute Myocardial Infarction Biological: Dose A Biological: Placebo Phase 2

Detailed Description:
This is a prospective, randomized, two arm, placebo-controlled, double blind, study that will enroll approximately 216 patients at no more than thirty-five (35) international clinical sites. Additional blinding measures will be taken in the assessment of study outcomes. The dose of the test material (ADRCs)is described in the protocol. The study will include two arms.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Safety and Efficacy of ADRCs Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction - The ADVANCE Study
Study Start Date : September 2012
Actual Primary Completion Date : May 2014
Actual Study Completion Date : May 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Attack

Arm Intervention/treatment
Active Comparator: Dose A
Dose A
Biological: Dose A
Other Name: Adipose-Derived Regenerative Cells

Placebo Comparator: Placebo
Biological: Placebo
Placebo Comparator

Primary Outcome Measures :
  1. Reduction in Infarct Size [ Time Frame: 6 Months ]
    Reduction in infarct size at 6 months as measured by cardiac MRI

Secondary Outcome Measures :
  1. MACCE Rates [ Time Frame: Through 36 months ]
    Major Adverse Cardiac and Cerebral events (MACCE) is a composite clinical endpoint

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • ST-segment Elevation Myocardial Infarction (STEMI) Criteria:
  • Ischemic symptoms AND
  • ECG:
  • Development of pathologic Q waves on the ECG; or
  • ECG changes indicative of severe ischemia (ST segment elevation and/or depression); or
  • New left bundle branch block; AND
  • Creatine Phosphokinase Isoenzyme (MB Form) > 100 IU/L, or troponin >5x the upper limit of normal between admission and randomization
  • Successful revascularization of the culprit lesion in a major epicardial vessel

Key Exclusion Criteria:

  • More than 24 hours between PCI and start of liposuction
  • Prior myocardial infarction, cardiomyopathy, or a history of congestive heart failure
  • Pacemaker, ICD, or any other contra-indication for MRI
  • Patients with increased bleeding risk
  • Cardiogenic shock present post-index PCI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01216995

Layout table for location information
Erasmus University Medical Centrum
Rotterdam, Netherlands
Krakowski Szpital Specjalistyczny im. Jana Pawla II Oddzial Kliniczny Chorob Serca i Naczyn
Krakow, Poland, 31202
Szpital Uniwersytecki Samodzielna Pracownia Zakladu Hemodynamiki
Krakow, Poland, 31501
Samodzielny Publiczny Centralny Szpital Kliniczny Pracownia Kardiologii Inwazyjnej
Warsaw, Poland, 02097
Sponsors and Collaborators
Cytori Therapeutics
Layout table for investigator information
Study Director: Steven Kesten, MD Cytori Therapeutics
Layout table for additonal information
Responsible Party: Cytori Therapeutics Identifier: NCT01216995    
Other Study ID Numbers: ADVANCE
First Posted: October 8, 2010    Key Record Dates
Last Update Posted: November 21, 2014
Last Verified: November 2014
Keywords provided by Cytori Therapeutics:
Heart Attack
Regenerative Cells
Stem Cells
Additional relevant MeSH terms:
Layout table for MeSH terms
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases